Ethyl-pyruvate reduces lung injury matrix metalloproteinases and cytokines and improves survival in experimental model of severe acute pancreatitis

Acta Cir Bras. 2013 Aug;28(8):559-67. doi: 10.1590/s0102-86502013000800002.

Abstract

Purpose: To investigate if the ethyl-pyruvate solution could reduce mortality in AP and/or diminish the acute lung injury.

Methods: Forty male rats, weighing between 270 to 330 grams were operated. An experimental model of severe AP by injection of 0.1 ml/100g of 2.5% sodium taurocholate into the bilio-pancreatic duct was utilized. The rats were divided into two groups of ten animals each: CT - control (treatment with 50 ml/kg of Ringer's solution, intraperitoneal) and EP (treatment with 50 ml/kg of Ringer ethyl-pyruvate solution, intra-peritoneal), three hours following AP induction. After six hours, a new infusion of the treatment solution was performed in each group. Two hours later, the animals were killed and the pulmonary parenchyma was resected for biomolecular analysis, consisting of: interleukin, myeloperoxidase, MDA, nitric oxide, metalloproteinases and heat shock protein. In the second part of the experiment, another, 20 rats were randomly divided into EP and CT groups, in order to evaluate a survival comparison between the two groups.

Results: There were no significant differences in IL-1B,IL-10, MMP-9, HSP70, nitric oxide, MPO, MDA (lipidic peroxidation) concerning both groups. The levels of IL-6 were significantly diminished in the EP group. Furthermore, the MMP-2 levels were also reduced in the EP group (p<0.05). The animals from the EP treatment groups had improved survival, when compared to control group (p<0.05).

Conclusion: The ethyl-pyruvate diminishes acute lung injury inflammatory response in acute pancreatitis and ameliorates survival when compared to control group, in the experimental model of necrotizing acute pancreatitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / chemically induced
  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / enzymology
  • Animals
  • Cytokines / metabolism*
  • Disease Models, Animal
  • Immunoblotting
  • Isotonic Solutions / pharmacology
  • Kaplan-Meier Estimate
  • Male
  • Matrix Metalloproteinases / metabolism*
  • Pancreatitis, Acute Necrotizing / drug therapy*
  • Pancreatitis, Acute Necrotizing / mortality
  • Pyruvates / pharmacology*
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Reference Values
  • Reproducibility of Results
  • Time Factors
  • Treatment Outcome

Substances

  • Cytokines
  • Isotonic Solutions
  • Pyruvates
  • Ringer's ethyl pyruvate
  • ethyl pyruvate
  • Matrix Metalloproteinases